Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers
Andreas Machens
Department of General, Visceral and Vascular Surgery, Martin-Luther-University, Halle (Saale),
Search for more papers by this authorLudwig Schaaf
Department of Endocrinology and Clinical Chemistry, Max-Planck-Institute for Psychiatry, Munich,
Search for more papers by this authorWolfram Karges
Division of Endocrinology, Department of Internal Medicine, University of Ulm, Ulm,
Search for more papers by this authorDetlef K. Bartsch
Department of Visceral, Thoracic, and Vascular Surgery, Phillipps University, Marburg,
Search for more papers by this authorMatthias Rothmund
Department of Visceral, Thoracic, and Vascular Surgery, Phillipps University, Marburg,
Search for more papers by this authorUlrich Schneyer
Division of Endocrinology, Department of Internal Medicine, Martin-Luther-University, Halle (Saale),
Search for more papers by this authorPeter Goretzki
Department of General and Trauma Surgery, Heinrich Heine University, Düsseldorf, Germany
Search for more papers by this authorHenning Dralle
Department of General, Visceral and Vascular Surgery, Martin-Luther-University, Halle (Saale),
Search for more papers by this authorAndreas Machens
Department of General, Visceral and Vascular Surgery, Martin-Luther-University, Halle (Saale),
Search for more papers by this authorLudwig Schaaf
Department of Endocrinology and Clinical Chemistry, Max-Planck-Institute for Psychiatry, Munich,
Search for more papers by this authorWolfram Karges
Division of Endocrinology, Department of Internal Medicine, University of Ulm, Ulm,
Search for more papers by this authorDetlef K. Bartsch
Department of Visceral, Thoracic, and Vascular Surgery, Phillipps University, Marburg,
Search for more papers by this authorMatthias Rothmund
Department of Visceral, Thoracic, and Vascular Surgery, Phillipps University, Marburg,
Search for more papers by this authorUlrich Schneyer
Division of Endocrinology, Department of Internal Medicine, Martin-Luther-University, Halle (Saale),
Search for more papers by this authorPeter Goretzki
Department of General and Trauma Surgery, Heinrich Heine University, Düsseldorf, Germany
Search for more papers by this authorHenning Dralle
Department of General, Visceral and Vascular Surgery, Martin-Luther-University, Halle (Saale),
Search for more papers by this authorCurrent address: Division of Endocrinology and Diabetology, Department of Medicine, RWTH, Aachen, §§Department of Surgery, Städtische Kliniken Bielefeld-Mitte, Bielefeld, ¶¶Department of Surgery, Lukas Hospital, Neuss, Germany
Summary
Objective In multiple endocrine neoplasia type 1 (MEN1), age-related tumour penetrance according to the type of MEN1 germline mutation has not been investigated in-depth. This study was conducted to examine whether carriers of out-of-frame/truncating and in-frame MEN1 mutations differ in age-related tumour penetrance.
Design A multicentre study with biochemical, hormonal and radiological screening for MEN1-associated tumours.
Patients A total of 258 MEN1 carriers from six major German tertiary referral centres averaging 43 years of age at last follow-up.
Measurements Main outcome measure was time to first diagnosis of MEN1-associated tumours.
Results Independent of the year of birth and observation period, time to first tumour diagnosis did not vary much by the type of MEN1 germline mutation or endocrine organ system, and perhaps not even by the type of endocrine tumour when the amount of time was considered by which the diagnosis probably has been advanced through the manifestation of hormonal symptoms. Parathyroid hyperplasia and adenomas developed almost twice as often as enteropancreatic and pituitary tumours (77%vs. 49–32%), and more than five to sevenfold as often as adrenal cortical tumours and carcinoids (77%vs. 15–10%), reaching penetrance rates of up to 90%, 60%, 40%, 26% and 17%, respectively. The heterogeneity of tumour penetrance was marked, ranging from 9 years to 25 years for the earliest, and from 68 years to 77 years for the latest tumour manifestation.
Conclusions Because of our inability of predicting tumour penetrance and malignant transformation individually, life-long follow-up of MEN1 carriers is warranted to prevent tumour morbidity.
References
- 1 Kouvaraki, M.A., Lee, J.E., Shapiro, S.E., Gagel, R.F., Sherman, S.I., Sellin, R.V., Cote, G.J. & Evans, D.B. (2002) Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Archives of Surgery, 137, 641–647.
- 2 Agarwal, S.K., Burns, A.L., Sukhodolets, K.E., Kennedy, P.A., Obungu, V.H., Hickman, A.B., Mullendore, M.E., Whitten, I., Skarulis, M.C., Simonds, W.F., Mateo, C., Crabtree, J.S., Scacheri, P.C., Ji, Y., Novotny, E.A., Garrett-Beal, L., Ward, J.M., Libutti, S.K., Alexander, H.R., Cerrato, A., Parisi, M.J., Santa Anna, A.S., Oliver, B., Chandrasekharappa, S.C., Collins, F.S., Spiegel, A.M. & Marx, S.J. (2004) Molecular pathology of the MEN1 gene. Annals of the New York Academy of Sciences, 1014, 189–198.
- 3 Yaguchi, H., Ohkura, N., Takahashi, M., Nagamura, Y., Kitabayashi, I. & Tsukada, T. (2004) Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway. Molecular and Cellular Biology, 24, 6569–6580.
- 4 La, P., Desmond, A., Hou, Z., Silva, A.C., Schnepp, R.W. & Hua, X. (2006) Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression. Oncogene, 25, 3537–3546.
- 5 Scacheri, P.C., Davis, S., Odom, D.T., Crawford, G.E., Perkins, S., Halawi, M.J., Agarwal, S.K., Marx, S.J., Spiegel, A.M., Meltzer, P.S. & Collins, F.S. (2006) Genome-wide analysis of menin binding provides insight into MEN1 tumorigenesis. PLoS Genetics, 2, e51.
- 6 Ratineau, C., Bernard, C., Poncet, G., Blanc, M., Josso, C., Fontanière, S., Calender, A., Chayvialle, J.A., Zhang, C.X. & Roche, C. (2004) Reduction of menin expression enhances cell proliferation and is tumorigenic in intestinal epithelial cells. Journal of Biological Chemistry, 23, 24477–24484.
- 7 Namihira, H., Sato, M., Murao, K., Cao, W.M., Matsubara, S., Imachi, H., Niimi, M., Dobashi, H., Wong, N.C.W. & Ishida, Z. (2002) The multiple endocrine neoplasia type 1 gene product, menin, inhibits the human prolactin promotor activity. Journal of Molecular Endocrinology, 29, 297–304.
- 8 Crabtree, J.S., Scacheri, P.C., Ward, J.M., Garrett-Beal, L., Emmert-Buck, M.R., Edgemon, K.A., Lorang, D., Libutti, S.K., Chandrasekharappa, S.C., Marx, S.J., Spiegel, A.M. & Collins, F.S. (2001) A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. PNAS, 98, 1118–1123.
- 9 Bertolino, P., Tong, W.M., Herrera, P.L., Casse, H., Zhang, C.X. & Wang, Z.Q. (2003) Pancreatic β-cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice. Cancer Research, 63, 4836–4841.
- 10 Bertolino, P., Tong, W.M., Galendo, D., Wang, Z.Q. & Zhang, C.X. (2003) Heterozygous MEN1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Molecular Endocrinology, 17, 1880–1892.
- 11 Biondi, C.A., Gartside, M.G., Waring, P., Loffler, K.A., Stark, M.S., Magnuson, M.A., Kay, G.F. & Hayward, N.K. (2004) Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues. Molecular and Cellular Biology, 24, 3125–3131.
- 12 Vergès, B., Boureille, F., Goudet, P., Murat, A., Beckers, A., Sassolas, G., Cougard, P., Chambe, B., Montvernay, C., Calender, A. & the members of Groupe d’Etude des Néoplasies Endocriniennes Multiples (2002) Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. Journal of Clinical Endocrinology and Metabolism, 87, 457–465.
- 13 Giraud, S., Zhang, C.X., Serova-Sinilnikova, O., Wautot, V., Salandre, J., Buisson, N., Waterlot, C., Bauters, C., Porchet, N., Aubert, J.P., Emy, P., Cadiot, G., Delemer, B., Chabre, O., Niccoli, P., Leprat, F., Duron, F., Emperauger, B., Cougard, P., Goudet, P., Sarfati, E., Riou, J.P., Guichard, S., Rodier, M., Meyrier, A., Caron, P., Vantyghem, M.C., Assayag, M., Peix, J.L., Pugeat, M., Rohmer, V., Vallotton, M., Lenoir, G., Gaudray, P., Proye, C., Conte-Devolx, B., Chanson, P., Shugart, Y.Y., Goldgar, D., Murat, A. & Calender, A. (1998) Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. American Journal of Human Genetics, 63, 455–467.
- 14 Wautot, V., Vercherat, C., Lespinasse, J., Chambe, B., Lenoir, G.M., Zhang, C.X., Porchet, N., Cordier, M., Béroud, C. & Calender, A. (2002) Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Human Mutation, 20, 35–47.
- 15 Feinstein, A.R., Sosin, D.M. & Wells, C.K. (1985) The Will Rogers phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. New England Journal of Medicine, 312, 1604–1608.
- 16 Guru, S.C., Manickam, P., Crabtree, J.S., Olufemi, S.E., Agarwal, S.K. & Debelenko, L.V. (1998) Identification and characterization of the multiple endocrine neoplasia type 1 (MEN1) gene. Journal of Internal Medicine, 243, 433–439.
- 17 Agarwal, S.K., Kester, M.B., Debelenko, L.V., Heppner, C., Emmert-Buck, M.R., Skarulis, M.C., Doppman, J.L., Kim, Y.S., Lubensky, I.A., Zhuang, Z., Green, J.S., Guru, S.C., Manickam, P., Olufemi, S.E., Liotta, L.A., Chandrasekharappa, S.C., Collins, F.S., Spiegel, A.M., Burns, A.L. & Marx, S.J. (1997) Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Human Molecular Genetics, 6, 1169–1175.
- 18 Chandrasekharappa, S.C., Guru, S.C., Manickham, P., Olufemi, S.E., Collins, F.S., Emmert-Buck, M.R., Debelenko, L.V., Zhuang, Z., Lubensky, I.A., Liotta, L.A., Crabtree, J.S., Wang, Y., Roe, B.A., Weisemann, J., Boguski, M.S., Agarwal, S.K., Kester, M.B., Kim, Y.S., Heppner, C., Dong, Q., Spiegel, A.M., Burns, A.L. & Marx, S.J. (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science, 276, 404–407.
- 19
Mutch, M.G.,
Dilley, W.G.,
Sanjurjo, F.,
DeBenedetti, M.K.,
Doherty, G.M.,
Wells, S.A. Jr,
Goodfellow, P.J. &
Lairmore, T.C. (1999) Germline mutations in the multiple endocrine neoplasia type 1 gene: evidence for frequent splicing defects.
Human Mutation, 13, 175–185.
10.1002/(SICI)1098-1004(1999)13:3<175::AID-HUMU1>3.0.CO;2-R CAS PubMed Web of Science® Google Scholar
- 20 Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457–481.
- 21 Schussheim, D.H., Skarulis, M.C., Agarwal, S.K., Simonds, W.F., Burns, A.L., Spiegel, A.M. & Marx, S.J. (2001) Multiple endocrine neoplasia type 1: new clinical and basic findings. TRENDS in Endocrinology and Metabolism, 12, 173–178.
- 22 Stratakis, C., Schussheim, D.H., Freedman, S.M., Keil, M.F., Pack, S.D., Agarwal, S.K., Skarulis, M.C., Weil, R.J., Lubensky, I.A., Zhuang, Z., Oldfield, E.H. & Marx, S.J. (2000) Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. Journal of Clinical Endocrinology and Metabolism, 85, 4776–4780.
- 23 Machens, A., Niccoli-Sire, P., Hoegel, J., Frank-Raue, K., Van Vroonhoven, T.J., Roeher, H.D., Wahl, R.A., Lamesch, P., Raue, F., Conte-Devolx, B. & Dralle, H., for the European Multiple Endocrine Neoplasia ( EUROMEN) study group (2003) Early malignant progression of hereditary medullary thyroid cancer. New England Journal of Medicine, 349, 1517–1525.
- 24 Jensen, R.T. (1998) Management of the Zollinger–Ellison syndrome in patients with multiple endocrine neoplasia type I. Journal of Internal Medicine, 243, 477–488.
- 25 Katona, T.M., Jones, T.D., Wang, M., Abdul-Karim, F.W., Cummings, O.W. & Cheng, L. (2006) Molecular evidence for independent origin of multifocal neuroendocrine tumors of the enteropancreatic axis. Cancer Research, 66, 4936–4942.
- 26 Anlauf, M., Schlenger, R., Perren, A., Bauersfeld, J., Koch, C.A., Dralle, H., Raffel, A., Knoefel, W.T., Weihe, E., Ruszniewski, P., Couvelard, A., Komminoth, P., Heitz, P.U. & Klöppel, G. (2006) Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. American Journal of Surgical Pathology, 30, 560–574.
- 27 Gauger, P.G., Scheiman, J.M., Wamsteker, E.J., Richards, M.L., Doherty, G.M. & Thompson, N.W. (2003) Role of endoscopic ultrasonography in screening and treatment of pancreatic endocrine tumours in asymptomatic patients with multiple endocrine neoplasia type 1. British Journal of Surgery, 90, 748–754.
- 28 Hellman, P., Hennings, J., Åkerström, G. & Skogseid, B. (2005) Endoscopic ultrasonography for evaluation of pancreatic tumours in multiple endocrine neoplasia type 1. British Journal of Surgery, 92, 1508–1512.
- 29 Bartsch, D.K., Fendrich, V., Langer, P., Celik, I., Kann, P.H. & Rothmund, M. (2005) Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Annals of Surgery, 242, 757–766.
- 30 Tonelli, F., Fratini, G., Nesi, G., Tommasi, M.S., Batignati, G., Falchetti, A. & Brandi, M.L. (2006) Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Annals of Surgery, 244, 61–70.
- 31 Norton, J.A., Alexander, H.R., Fraker, D.L., Venzon, D.J., Gibril, F. & Jensen, R.T. (2001) Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger–Ellison syndrome. Annals of Surgery, 234, 495–505; discussion 505–506.
- 32 Brandi, M.L., Gagel, R.F., Angeli, A., Bilezikian, J.P., Beck-Peccoz, P., Bordi, C., Conte-Devolx, B., Falchetti, A., Gheri, R.G., Libroia, A., Lips, C.J.M., Lombardi, G., Mannelli, M., Pacini, F., Ponder, B.A.J., Raue, F., Skogseid, B., Tamburrano, G., Thakker, R.V., Thompson, N.W., Tomassetti, P., Tonelli, F., Wells, S.A. & Marx, S.J. (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism, 86, 5658–5671.
Citing Literature
